Skip to main content
Disciplines
Automotive Business IT + Informatics Construction + Real Estate Electrical Engineering + Electronics Energy + Sustainability Insurance + Risk Finance + Banking Management + Leadership Marketing + Sales Mechanical Engineering + Materials
Events
DE
EN
Books
Journals
Topic Page
Marketing
Start single access now
Access for companies
EXTENDED SEARCH
Log in
Top
Polymer Bulletin
Published in: Polymer Bulletin 10/2023

21-11-2022 | REVIEW PAPER

The evolution of the global COVID-19 epidemic in Morocco and understanding the different therapeutic approaches of chitosan in the control of the pandemic

Authors: Youssef Ait Hamdan, Fatima El Amerany, Jacques Desbrières, Abdessadek Aghrinane, Hassane Oudadesse, Mohammed Rhazi

Published in: Polymer Bulletin | Issue 10/2023

Log in

Activate our intelligent search to find suitable subject content or patents.

search-config
loading …

Abstract

In 2020, Coronavirus disease (COVID-19), a new viral respiratory disease caused by a virus that belongs to Coronaviridae family, has been identified. It is a very severe flu that negatively affects the functions of the lung and other respiratory organs. COVID-19 virus can be transmitted between people either by touching an infected person or by direct contact with their respiratory droplets. Therefore, the COVID-19 virus has become a global concern due to its rapid spread and severity. Based on the World Health Organization report from 2 March 2020 to 24 October 2022, the total infected cases and deaths in Morocco are around 1,265,389 (3.46%) and 16,280 (0.04%), respectively. Recently, some scientists have found that chitosan, a polymer existed in nature, can inhibit COVID-19 infection and repair damaged tissue. Therefore, understanding chitosan mechanisms in controlling COVID-19, might lead to innovative strategies in the medical field, such as developing drugs against SARS-CoV-2, and replacing vaccines, which have negative side effects. This review aims to show the evolution of the COVID-19 pandemic worldwide, specifically in Morocco, its pathophysiology, and its ability to silence the immune system. This review also provides an overview of the treatments and measures applied to protect human beings and how chitosan acts and controls COVID-19.
previous article Hydrogels and biohydrogels: investigation of origin of production, production methods, and application
next article Polyamide (PA)- and Polyimide (PI)-based membranes for desalination application

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

inform now

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

inform now
Literature
1.
Bansal M (2020) Cardiovascular disease and COVID-19. Diabetes Metabol Syndr Clin Res Rev 14:247–250CrossRef
2.
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q et al (2020) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 77:683–690PubMedCrossRef
3.
4.
Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS et al (2020) Extrapulmonary manifestations of COVID-19. Nat Med 26:1017–1032PubMedCrossRef
5.
6.
Murs AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D (2020) Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein. Cellule 181(2):281–292CrossRef
7.
Letko M, Marzi A, Munster V (2020) Functional assessment of cell entry and receptor utilization for SARS-CoV-2 and other lineage B betacoronaviruses. Microbiol Nat 5(4):562–569CrossRef
8.
Sharma N, Modak C, Singh PK, Kumar R, Khatri D, Singh SB (2021) Underscoring the immense potential of chitosan in fighting a wide spectrum of viruses: a plausible molecule against SARS-CoV-2? Int J BiolMacromol 179:33–44CrossRef
9.
Jawad AH, Rangabhashiyam S, Abdulhameed AS, Syed-Hassan SSA, ALOthman ZA, Wilson LD (2022) Process optimization and adsorption mechanism for blue reactive dye 19 by magnetically crosslinked chitosan/MgO/Fe3O4 biocomposite. J Polym Environ 30(7):2759–2773CrossRef
10.
Abdulhameed AS, Jawad AH, Ridwan M, Khadiran T, Wilson LD, Yaseen ZM (2022) Chitosan/carbon-doped TiO2 composite for adsorption of two anionic dyes in solution and gaseous SO2 capture: experimental modeling and optimization. J Polym Environ 30(11):4619–4636CrossRef
11.
Abdulhameed AS, Jawad AH, Vigneshwaran S, ALOthman ZA, Yaseen ZM (2022) Différentes phases de TiO2 (Degussa/Anatase) Composite de chitosane réticulé modifié pour l'élimination du colorant réactif Red 4 : Box–Behnken Design. Journal des polymères et de l'environnement 1–16
12.
Jawad AH, Moubarak NSA, Abdulhameed AS (2020) Tunable Schiff-based cross-linked chitosan composite for removal of reactive dye red 120: adsorption and mechanism study. Int Rev Biol Macromol 142:732–741CrossRef
13.
Jawad AH, Abdulhameed AS, Reghioua A, Yaseen ZM (2020) Zwitterion composite chitosan-epichlorohydrin/zeolite for adsorption of methylene blue and reactive red 120 dyes. Int J Biol Macromol 163:756–765PubMedCrossRef
14.
Jawad AH, Abdulhameed AS (2020) Facile synthesis of crosslinked chitosan-tripolyphosphate/kaolin clay composite for decolourization and COD reduction of remazol brilliant blue R dye: optimization by using response surface methodology. Colloids Surf A 605:125329CrossRef
15.
Jawad AH, Abdulhameed AS, Abd Malek NN, ALOthman ZA (2020) Statistical optimization and modeling for color removal and COD reduction of blue reactive dye 19 by a mesoporous chitosan-epichlorohydrin/kaolin clay composite. Int J Biol Macromol 164:4218–4230PubMedCrossRef
16.
Jawad AH, Abdulhameed AS, Wilson LD, Hanafiah MAKM, Nawawi WI, ALOthman ZA, Rizwan Khan M (2021) Fabrication of a Schiff-based chitosan-glutaraldehyde/active carbon composite for cationic dye removal: optimization using response surface methodology. J Polym Environ 29(9):2855–2868CrossRef
17.
Jawad AH, Abdulhameed AS, Kashi E, Yaseen ZM, ALOthman ZA, Khan MR (2022) Cross-linked chitosan-glyoxal/kaolin composite: parametric optimization for color removal and COD reduction of remazole brilliant blue dye R. J Polym Environ 30(1):164–178CrossRef
18.
Reghioua A, Barkat D, Jawad AH, Abdulhameed AS, Khan MR (2021) Synthesis of magnetically crosslinked Schiff-based chitosan-glyoxal/ZnO/Fe3O4 nanoparticles for enhanced organic dye adsorption: modeling and mechanism study. Sustain Chem Pharm 20:100379CrossRef
19.
Reghioua A, Barkat D, Jawad AH, Abdulhameed AS, Rangabhashiyam S, Khan MR, ALOthman ZA (2021) Magnetic chitosan-glutaraldehyde/zinc oxide/Fe3O4 nanocomposite: optimization and adsorptive mechanism of remazol brilliant blue R dye removal. J Polym Environ 29(12):3932–3947CrossRef
20.
Jawad AH, Abdulhameed AS, Selvasembian R, ALOthman ZA, Wilson LD (2022) Chitosan-diglycidyl ethylene glycol/magnesium oxide/Fe3O4 magnetic biohybrid nanocomposite for textile dye removal: optimization of the Box–Behnken design and mechanism study. J Polym Res 29(5):1–15CrossRef
21.
Jawad AH, Hameed BH, Abdulhameed AS (2022) Synthesis of biohybrid magnetic chitosan-polyvinyl alcohol/MgOnanocomposite blend for remazol brilliant blue R dye adsorption: solo and collective parametric optimization. Polym Bull 1–21
22.
Jawad, AH, Abdulhameed, AS, Surip, SN et Sabar, S (2020) Performance d'adsorption du biopolymère de chitosane modifié au carbone pour l'élimination des colorants cationiques : étude cinétique, isotherme, thermodynamique et des mécanismes. Journal international de chimie analytique environnementale 1–15
23.
Reghioua A, Barkat D, Jawad AH, Abdulhameed AS, Al-Kahtani AA, ALOthman ZA (2021) Parametric optimization by Box–Behnken design for synthesis of magnetic chitosan-benzil/ZnO/Fe3O4 nanocomposite and textile dye removal. J Environ Chem Eng 9(3):105166CrossRef
24.
Chiari W, Damayanti R, Harapan H, Puspita K, Saiful S, Rahmi R, Rizki DR, Iqhrammullah M (2022) Trend of polymer research related to COVID-19 Pandemic: bibliometric analysis. Polymers 14(16):3297PubMedPubMedCentralCrossRef
25.
26.
Allam Z (2020) The first 50 days of COVID-19: A detailed chronological timeline and extensive review of literature documenting the pandemic. In: Allam Z (ed) Surveying the COVID-19 Pandemic and its Implications. Elsevier, Australia, pp 1–7
27.
Lytras S, Xia W, Hughes J, Jiang X, Robertson DL (2021) The animal origin of SARS-CoV-2. Science 373:968–970PubMedCrossRef
28.
Sebbani M, Adarmouch L, Mansouri A, Amine M (2020) Evolution of COVID-19 in relation to public health countermeasures in Morocco. Open J Epidemiol 10:187–194CrossRef
29.
Rao S, Singh M (2021) The newly detected B. 1.1. 529 (Omicron) variant of sars-cov-2 with multiple mutations. In: DHR proceedings, vol 1, pp 7–10
30.
Ait Addi R, Benksim A, Amine M, Cherkaoui M (2020) COVID-19 outbreak and perspective in Morocco. Electron J Gen Med 17:em204CrossRef
31.
Melloul M, Chouati T, Hemlali M, Alaoui Amine S, Touil N, Elannaz H et al (2021) Genome Sequences of the Delta Variant (B. 1.617. 2) and the Kappa Variant (B. 1.617. 1) Detected in Morocco. Microbiol Resour Announc 10:e00727-e821PubMedPubMedCentralCrossRef
32.
Kuniya T (2020) Evaluation of the effect of the state of emergency for the first wave of COVID-19 in Japan. Infect Dis Model 5:580–587PubMedPubMedCentral
33.
Kwak N, Hwang SS, Yim JJ (2020) Effect of COVID-19 on tuberculosis notification. South Korea Emerg Infect Dis 26:2506PubMedCrossRef
34.
Andrews MA, Areekal B, Rajesh KR, Krishnan J, Suryakala R, Krishnan B et al (2020) First confirmed case of COVID-19 Infection in India: a case report. Indian J Med Res 151:490PubMedPubMedCentralCrossRef
35.
Saberian P, Conovaloff JL, Vahidi E, Hasani-Sharamin P, Kolivand PH (2020) How the COVID-19 epidemic affected prehospital emergency medical services in Tehran, Iran. West J Emerg Med 21:110PubMedPubMedCentralCrossRef
36.
Spiteri G, Fielding J, Diercke M, Campese C, Enouf V, Gaymard A et al (2020) First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. Euro Surveill 25:2000178PubMedPubMedCentralCrossRef
37.
Redondo-Bravo L, Moros MJS, Sánchez EVM, Lorusso N, Ubago AC, García VG et al (2020) The first wave of the COVID-19 pandemic in Spain: characterisation of cases and risk factors for severe outcomes, as at April 27 2020. Euro Surveill 25(50):2001431PubMedCentral
38.
Indolfi C, Spaccarotella C (2020) The outbreak of COVID-19 in Italy: fighting the pandemic. Case Rep 2:1414–1418
39.
Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H et al (2020) First case of 2019 novel coronavirus in the United States. N Engl J Med 382:929–936PubMedPubMedCentralCrossRef
40.
41.
Suárez V, Suarez Quezada M, Oros Ruiz S, Ronquillo De Jesús E (2020) Epidemiology of COVID-19 in Mexico: from the 27th of February to the 30th of April 2020. Rev Clin Esp (Barc) 220:463–471PubMedCrossRef
42.
Gemelli NA (2020) Management of COVID-19 outbreak in Argentina: the beginning. Disaster Med Public Health Prep 14:815–817PubMedCrossRef
43.
Crokidakis N (2020) COVID-19 spreading in Rio de Janeiro, Brazil: do the policies of social isolation really work? Chaos Solit Fractals 136:109930CrossRef
44.
Cumming J (2021) Going hard and early: Aotearoa New Zealand's response to COVID-19. Health Econ Policy Law 17(1):107–119PubMedCrossRef
45.
46.
Aubry M, Teiti I, Teissier A, Richard V, Mariteragi-Helle T, Chung K et al (2021) Self-collection and pooling of samples as resources-saving strategies for RT-PCR-based SARS-CoV-2 surveillance, the example of travelers in French Polynesia. PLoS ONE 16:e0256877PubMedPubMedCentralCrossRef
47.
48.
49.
50.
Lounis M (2021) Epdemiology of coronavirus disease 2020 (COVID-19) in Algeria. New Microbes New Infect 39:100822PubMedCrossRef
51.
Jmaa MB, Ayed HB, Kassis M, Hmida MB, Trigui M, Maamri H et al (2021) Epidemiological profile and performance of triage decision-making process of COVID-19 suspected cases in southern Tunisia. Afr J Emerg Med 12:1–6PubMedPubMedCentralCrossRef
52.
Hadrya F, Soulaymani A, El Hattimy F. Space-time COVID-19 monitoring in Morocco. Pan Afr Med J. 2020;35.
53.
54.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger NT, Herrler S, Erichsen TS et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271–280PubMedPubMedCentralCrossRef
55.
Ruiz-Hitzky E, Darder M, Wicklein B, Ruiz-Garcia C, Martín-Sampedro R, Del Real G et al (2020) Nanotechnology responses to COVID-19. Adv Healthc Mater 9:2000979CrossRef
56.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet 395:497–506PubMedCrossRef
57.
58.
Ferrandi PJ, Always SE, Mohamed JS (2020) The interaction between SARS-CoV-2 and ACE2 may have consequences for skeletal muscle viral susceptibility and myopathies. J Appl Physiol 129:864–867PubMedPubMedCentralCrossRef
59.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395:507–513PubMedPubMedCentralCrossRef
60.
Heidarpour M, Vakhshoori M, Abbasi S, Shafie D, Rezaei N (2020) Adrenal insufficiency in coronavirus disease 2019: a case report. J Med Case Rep 14:1–4CrossRef
61.
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC (2020) Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 324:782–793PubMedCrossRef
62.
Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen MC et al (2020) Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy 75:1564–1581PubMedCrossRef
63.
64.
Loganathan S, Athalye SN, Joshi SR (2020) Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications. Expert Opin Biol Ther 20:1025–1031PubMedCrossRef
65.
Piotrowicz K, Gąsowski J (2020) Risk factors for frailty and cardiovascular diseases: are they the same? Adv Exp Med Biol 1216:39–50PubMedCrossRef
66.
67.
68.
Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X et al (2020) Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med 383:2291–2293PubMedCrossRef
69.
Elbe S, Buckland-Merrett G (2017) Data, disease and diplomacy: GISAID’s innovative contribution to global health. Glob Challenges 1:33–46CrossRef
70.
Yuan M, Wu NC, Zhu X, Lee CD, So RTY, Lv H et al (2020) A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 368:630–633PubMedPubMedCentralCrossRef
71.
Andreano E, Piccini G, Licastro D, Casalino L, Johnson NV, Paciello I et al (2021) SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. Proc Natl Acad Sci 118(36):e2103154118PubMedPubMedCentralCrossRef
72.
73.
El Khiat A, Ait Hamdan Y, Tamegart L, Draoui A, Aglagane A, El Fari R et al (2022) Therapeutic management of COVID-19 patients: In: El Hiba O, Radhakrishnan J, Balzano T, Isbaine F (eds) Handbook of research on pathophysiology and strategies for the management of COVID-19. IGI Global, pp 210–220
74.
Alshrari AS, Hudu SA, Imran M, Asdaq SMB, Ali AM, Rabbani SI (2022) Innovations and development of COVID-19 vaccines: a patent review. J Infect Public Health 15:123–131PubMedCrossRef
75.
Pollard AJ, Bijker EM (2021) A guide to vaccinology: from basic principles to new developments. Nat RevImmunol 21:83–100
76.
Saeedi-Boroujeni A, Mahmoudian-Sani MR (2021) Anti-inflammatory potential of Quercetin in COVID-19 treatment. J Inflamm 18:1–9CrossRef
77.
78.
Chen CX, Wang JJ, Li H, Yuan LT, Gale RP, Liang Y (2021) JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis. Leukemia 35:2616–2620PubMedPubMedCentralCrossRef
79.
Shen L, Qiu L, Liu D, Wang L, Huang H, Ge H et al (2021) The association of low molecular weight heparin use and in-hospital mortality among patients hospitalized with COVID-19. Cardiovasc Drugs Ther 36(1):113–120PubMedPubMedCentralCrossRef
80.
Huang Z, Fu Z, Wang J (2022) Review on drug regulatory science promoting COVID-19 vaccine development in china. Engineering 10:127–132CrossRef
81.
Mallapaty S (2021) China’s COVID vaccines are going global—but questions remain. Nature 593:178–179PubMedCrossRef
82.
83.
Cleve M (2021) What the lightning-fast quest for Covid vaccines means for other diseases. Nature 589:16–18CrossRef
84.
Schoenmaker L, Witzigmann D, Kulkarni JA, Verbeke R, Kersten G, Jiskoot W et al (2021) mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J Pharm 601:120586PubMedPubMedCentralCrossRef
85.
Wang Z, Liu H, Li Y, Luo X, Yang N, Lv M et al (2021) COVID-19 vaccine guidelines was numerous in quantity but many lack transparent reporting of methodological practices. J Clin Epidemiol 144:163–172PubMedPubMedCentralCrossRef
86.
Sen-Crowe B, McKenney M, Elkbuli A (2021) Disparities in global COVID-19 vaccination rates & allocation of resources to countries in need. Ann Med Surg 68:102620CrossRef
87.
Dehbi ZEO, Sedrati H, Chaqsare S, Azami AI, Merzouki M, Raji M et al (2021) Moroccan digital health response to the COVID-19 crisis. Front Public Health 9:690462CrossRef
88.
Hammoumi A, Hmarrass H, Qesmi R (2021) Impact of booster COVID-19 vaccine for Moroccan adults: a discrete age-structured model approach. MedRxiv
89.
Mallapaty S (2021) China’s COVID vaccines have been crucial—now immunity is waning. Nature 598:398–399PubMedCrossRef
90.
Agyekum MW, Afrifa-Anane GF, Kyei-Arthur F, Addo B (2021) Acceptability of COVID-19 vaccination among health care workers in Ghana. Adv Public Health 2021
91.
92.
Rhazi M, Desbrieres J, Tolaimate A, Alagui A, Vottero P (2000) Investigation of different natural sources of chitin: influence of the source and deacetylation process on the physicochemical characteristics of chitosan. Polym Int 49(4):337–344CrossRef
93.
Arrouze F, Desbrieres J, Rhazi M, Essahli M, Tolaimate A (2019) Valorisation des chitines extraites des crevettes du Nord Maroc : Comparaison de la réactivité et des caractéristiques de la chitine. J Appl Polym Sci 136(30):47804CrossRef
94.
Safarzadeh M, Sadeghi S, Azizi M, Rastegari-Pouyani M, Pouriran R, Hoseini MHM (2021) Chitin and chitosan as tools to combat COVID-19: A triple approach. Int J Boil Macromol 2021(183):235–244CrossRef
95.
Pieklarz K, Modrzejewska Z (2021) Sars-Cov-2–the latest global threat and the prospect of COVID-19 therapy with the use of chitosan. Progr Chem Appl Chitin Deriv 26:41–60
96.
Shibata Y, Foster LA, Metzger WJ, Myrvik QN (1997) Alveolar macrophage priming by intravenous administration of chitin particles, polymers of N-acetyl-D-glucosamine, in mice. Infect Immun 65:1734–1741PubMedPubMedCentralCrossRef
97.
Bacon A, Makin J, Sizer PJ, Jabbal-Gill I, Hinchcliffe M, Illum L et al (2000) Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun 68:5764–5770PubMedPubMedCentralCrossRef
98.
Moran HB, Turley JL, Andersson M, Lavelle EC (2018) Immunomodulatory properties of chitosan polymers. Biomaterials 184:1–9PubMedCrossRef
99.
Bueter CL, Lee CK, Wang JP, Ostroff GR, Specht CA et al (2014) Spectrum and mechanisms of inflammasome activation by chitosan. J Immunol 192:5943–5951PubMedCrossRef
100.
Kumar M, Behera AK, Lockey RF, Zhang J, Bhullar G, De La Cruz CP et al (2002) Intranasal gene transfer by chitosan–DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum Gene Therapy 13:1415–1425CrossRef
101.
Iqbal M, Lin W, Jabbal-Gill I, Davis SS, Steward MW et al (2003) Nasal delivery of chitosan–DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine 21:1478–1485PubMedCrossRef
102.
Ghendon Y, Markushin S, Krivtsov G, Akopova I (2008) Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines. Arch Virol 153:831–837PubMedCrossRef
103.
Sui Z, Chen Q, Fang F, Zheng M, Chen Z (2010) Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. Vaccine 28:7690–7698PubMedCrossRef
104.
Sui Z, Chen Q, Wu R, Zhang H, Zheng M, Wang H et al (2010) Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant. Arch Virol 155:535–544PubMedCrossRef
105.
Hagenaars N, Mania M, de Jong P, Que I, Nieuwland R, Slütter B et al (2010) Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine. J Control Release 144:17–24PubMedCrossRef
106.
Hagenaars N, Verheul RJ, Mooren I, de Jong PH, Mastrobattista E, Glansbeek HL et al (2009) Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine. J Control Release 140:126–133PubMedCrossRef
107.
Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, Huckriede A et al (2007) N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. Vaccine 25:144–153PubMedCrossRef
108.
Borges O, Tavares J, de Sousa A, Borchard G, Junginger HE, Cordeiro-da-Silva A (2007) Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. Eur J Pharm Sci 32:278–290PubMedCrossRef
109.
Gupta NK, Tomar P, Sharma V, Dixit VK (2011) Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza. Vaccine 29:9026–9037PubMedCrossRef
110.
Lopes PD, Okino CH, Fernando FS, Pavani C, Casagrande VM, Lopez RF et al (2018) Inactivated infectious bronchitis virus vaccine encapsulated in chitosan nanoparticles induces mucosal immune responses and effective protection against challenge. Vaccine 36:2630–2636PubMedCrossRef
111.
Moon HJ, Lee JS, Talactac MR, Chowdhury MY, Kim JH, Park ME et al (2012) Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus. Vet Microbiol 160:277–289PubMedCrossRef
112.
Debnath SK, Saisivam S, Debanth M, Omri A (2018) Development and evaluation of Chitosan nanoparticles based dry powder inhalation formulations of Prothionamide. PLoS ONE 13:e0190976PubMedPubMedCentralCrossRef
113.
Jaimes JA, Millet JK, Whittaker GR (2020) Proteolytic cleavage of the SARS-CoV-2 spike protein and the role of the novel S1/S2 site. IScience 23:101212PubMedPubMedCentralCrossRef
114.
Hathout RM, Kassem DH (2020) Positively charged electroceutical spun chitosan nanofibers can protect health care providers from COVID-19 infection: an opinion. Front Bioeng Biotechnol 8:885PubMedPubMedCentralCrossRef
115.
Milewska A, Ciejka J, Kaminski K, Karewicz A, Bielska D, Zeglen S et al (2013) Novel polymeric inhibitors of HCoV-NL63. Antivir Res 97:112–121PubMedCrossRef
116.
Milewska A, Chi Y, Szczepanski A, Barreto-Duran E, Liu K, Liu D et al (2020) HTCC as a highly effective polymeric inhibitor of SARS-CoV-2 and MERS-CoV. BioRxiv
117.
Itani R, Tobaiqy M, Al FA (2020) Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients. Theranostics 10:5932PubMedPubMedCentralCrossRef
118.
Pyrć K, Milewska A, Duran EB, Botwina P, Lopes R, ArenasPinto A et al (2020) SARS-CoV-2 inhibition in human airway epithelial cells using a mucoadhesive, amphiphilic chitosan that may serve as an antiviral nasal spray. bioRxiv (in press)
119.
Castells-Sala C, Alemany-Ribes M, Fernández-Muiños T, Recha-Sancho L, López-Chicón P, Aloy-Reverté C et al (2013) Current applications of tissue engineering in biomedicine. J Biochips Tiss Chips 1
120.
Roy HS, Singh R, Ghosh D (2021) SARS-CoV-2 and tissue damage: current insights and biomaterial-based therapeutic strategies. Biomater Sci 9:2804–2824PubMedCrossRef
121.
Lemon G, Lim ML, Ajalloueian F, Macchiarini P (2014) The development of the bioartificial lung. Br Med Bull 110:35–45PubMedCrossRef
122.
Sokocevic D, Bonenfant NR, Wagner DE, Borg ZD, Lathrop MJ, Lam YW et al (2013) The effect of age and emphysematous and fibrotic injury on the re-cellularization of de-cellularized lungs. Biomaterials 34:3256–3269PubMedPubMedCentralCrossRef
123.
Oudadesse H, Najem S, Mosbahi S, Rocton N, Refifi J, El Feki H et al (2021) Development of hybrid scaffold: Bioactive glass nanoparticles/chitosan for tissue engineering applications. J Biomed Mater Res A 109:590–599PubMedCrossRef
124.
Rezaei FS, Khorshidian A, Beram FM, Derakhshani A, Esmaeili J, Barati A (2021) 3D printed chitosan/polycaprolactone scaffold for lung tissue engineering: hope to be useful for COVID-19 studies. RSC Adv 11:19508–19520PubMedPubMedCentralCrossRef
125.
126.
Kargozar S, Singh RK, Kim HW, Baino F (2020) “Hard” ceramics for “Soft” tissue engineering: paradox or opportunity? Actabiomaterialia 115:1–28
127.
Saravanapavan P, Verrier S, Hench LL (2004) A549 lung carcinoma cells: binary vs. ternary bioactive gel-glasses. Key Eng Mater 254:781–784
128.
Zhou Z, Xiang L, Ou B, Huang T, Zhou H, Zeng W et al (2014) Biological assessment in-vivo of gel-HA scaffold materials containing nano-bioactive glass for tissue engineering. J Macromol Sci A 51:572–576CrossRef
129.
Tan A, Romanska HM, Lenza R, Jones JR, Hench LL, Polak JM et al (2003) The effect of 58S bioactive sol-gel derived foams on the growth of murine lung epithelial cells. Key Eng Mater 240:719–724CrossRef
130.
Verrier S, Blaker JJ, Maquet V, Hench LL, Boccaccini AR (2004) PDLLA/Bioglass® composites for soft-tissue and hard-tissue engineering: an in vitro cell biology assessment. Biomaterials 25:3013–3021PubMedCrossRef
131.
Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C et al (2020) Clinical features of COVID-19-related liver functional abnormality. Clin Gastroenterol Hepatol 18:1561–1566PubMedPubMedCentralCrossRef
132.
Lenti MV, Borrelli de Andreis F, Pellegrino I, Klersy C, Merli S, Miceli E et al (2020) Impact of COVID-19 on liver function: results from an internal medicine unit in Northern Italy. Intern Emerg Med 15:1399–1407PubMedPubMedCentralCrossRef
133.
134.
Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A et al (2020) Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. BioRxiv
135.
136.
Santhosh S, Sini TK, Anandan R, Mathew PT (2007) Hepatoprotective activity of chitosan against isoniazid and rifampicin-induced toxicity in experimental rats. Eur J Pharmacol 572:69–73PubMedCrossRef
137.
Jeon TI, Hwang SG, Park NG, Jung YR, Im Shin S, Choi SD et al (2003) Antioxidative effect of chitosan on chronic carbon tetrachloride induced hepatic injury in rats. Toxicology 187:67–73PubMedCrossRef
138.
Qiu Y, Mao Z, Zhao Y, Zhang J, Guo Q, Gou Z et al (2012) Polycaprolactone scaffold modified with galactosylated chitosan for hepatocyte culture. Macromol Res 20:283–291CrossRef
139.
140.
141.
Mahammedi A, Saba L, Vagal A, Leali M, Rossi A, Gaskill M et al (2020) Imaging of neurologic disease in hospitalized patients with COVID-19: an Italian multicenter retrospective observational study. Radiology 297:E270–E273PubMedCrossRef
142.
143.
Francesca M, Lia B, Antonio C (2020) Cerebral stroke with sepsis during COVID-19 Infection. Med Case Rep 2:143
144.
Neher MD, Weckbach S, Flierl MA, Huber-Lang MS, Stahel PF (2011) Molecular mechanisms of inflammation and tissue injury after major trauma-is complement the" bad guy"? J Biomed Sci 18:1–16CrossRef
145.
146.
Boni R, Ali A, Shavandi A, Clarkson AN (2018) Current and novel polymeric biomaterials for neural tissue engineering. J Biomed Sci 25:1–21CrossRef
147.
Xu H, Zhang L, Bao Y, Yan X, Yin Y, Li Y et al (2017) Preparation and characterization of injectable chitosan–hyaluronic acid hydrogels for nerve growth factor sustained release. J BioactCompat Polym 32:146–162
148.
Samadikuchaksaraei A (2007) An overview of tissue engineering approaches for management of spinal cord injuries. J NeuroEng Rehabil 4:1–16CrossRef
149.
Gennari CG, Cilurzo F, Mitro N, Caruso D, Minghetti P, Magnaghi V (2018) In vitro and in vivo evaluation of silk fibroin functionalized with GABA et al. lopregnanolone for Schwann cell and neuron survival. Regen Med 13:141–157PubMedCrossRef
150.
Crompton KE, Goud JD, Bellamkonda RV, Gengenbach TR, Finkelstein DI, Horne MK et al (2007) Polylysine-functionalisedthermoresponsive chitosan hydrogel for neural tissue engineering. Biomaterials 28:441–449PubMedCrossRef
151.
Valmikinathan CM, Mukhatyar VJ, Jain A, Karumbaiah L, Dasari M, Bellamkonda RV (2012) Photocrosslinkable chitosan based hydrogels for neural tissue engineering. Soft Matter 8:1964–1976PubMedCrossRef
152.
Kuo YC, Yeh CF, Yang JT (2009) Differentiation of bone marrow stromal cells in poly (lactide-co-glycolide)/chitosan scaffolds. Biomaterials 30:6604–6613PubMedCrossRef
153.
Xue C, Hu N, Gu Y, Yang Y, Liu Y, Liu J et al (2012) Joint use of a chitosan/PLGA scaffold and MSCs to bridge an extra large gap in dog sciatic nerve. Neurorehabil Neural Repair 26:96–106PubMedCrossRef
154.
Wang S, Sun C, Guan S, Li W, Xu J, Ge D, Ma X (2017) Porous chitosan/gelatin scaffolds assembled with conductive poly (3,4-ethylenedioxythiophene) nanoparticles for neuronal tissue engineering. J Mater Chem B 5(24):4774–4788PubMedCrossRef
Metadata
Title
The evolution of the global COVID-19 epidemic in Morocco and understanding the different therapeutic approaches of chitosan in the control of the pandemic
Authors
Youssef Ait Hamdan
Fatima El Amerany
Jacques Desbrières
Abdessadek Aghrinane
Hassane Oudadesse
Mohammed Rhazi
Publication date
21-11-2022
Publisher
Springer Berlin Heidelberg
Published in
Polymer Bulletin / Issue 10/2023
Print ISSN: 0170-0839
Electronic ISSN: 1436-2449
DOI
https://doi.org/10.1007/s00289-022-04579-3

Other articles of this Issue 10/2023

Polymer Bulletin 10/2023 Go to the issue

ORIGINAL PAPER

Thermal conductivity of epoxy composites modified by microspheric molybdenum disulfide

REVIEW PAPER

Hydrogels and biohydrogels: investigation of origin of production, production methods, and application

ORIGINAL PAPER

Organic acid and amino acid coated multi-nutrient fertilizer granules (MNFG): synthesis and characterization

ORIGINAL PAPER

Investigation of the physico-mechanical and moisture management properties of chemically treated cotton fabrics

ORIGINAL PAPER

Mechanical and dielectric properties of ECR-glass/polyimide-based composites

Original Paper

Poly(acrylamide-co-acrylic acid)-based gel polymer electrolytes incorporated with sodium iodide for dye-sensitized solar cells (DSSCs)

Premium Partners

    Image Credits